Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. by Plu-Bureau, G. et al.
Br. J. Cancer (1994), 70, 270-277 C) Macmillan Press Ltd., 1994
Progestogen use and decreased risk of breast cancer in a cohort study of
premenopausal women with benign breast disease
G. Plu-Bureaul'2, M.G. La', R. Sitruk-Ware&, J.C. Thalabard3 & P. Mauvais-Jarvis2
'INSERM. U351, Gustave-Roussy Institute, 94805 Vdlejuif, France; 2Department ofReproductive Endocrinology, Necker
Hospital, 75015 Paris, France; 3Clinical Pharmacology, HCL-Lyon I University, 69003 Lyon, France.
S_ry A cohort study of 1,150 premenopausal French women with benign breast disease diagnosed in
two breast clinics between 1976 and 1979 was carried out to analyse the relationship between progestogen use
and the risk of breast cancer. The follow-up accumulated 12,462 person-years. The risk of breast cancer was
estimated using a Poisson regression analysis on person-time data and the proportional hazards model. In the
latter analysis, cumulated progestogen use and age were considered as time-varying covariables and adjustment
was performed on the main risk factors for breast cancer. Neither overall progestogen use nor the duration of
use was found to be significantly associated with the risk of breast cancer. When progestogens were classified
into two categories according to their hormonal potency (19-nortestosterone derivatives vs other proges-
togens), 19-nortestosterone derivative use was found to be significantly associated with a lower risk of breast
cancer. In the adjusted model, the corresponding risk of breast cancer was 0.48 (95% confidence interval
0.25-0.90). In addition, there was a linear trend in the decrease of the relative risk of breast cancer with the
duration of use (P = 0.02). These results do not support the hypothesis that progestogens might increase the
breast cancer risk. They suggest, instead, that treatment with 19-nortestosterone derivatives might have a
beneficial effect on the risk of breast cancer in women with benign breast diseas.
The high incidence of breast cancer in developed countries
together with the slow progress in its treatment have
stimulated interest in the exploration and validation of
methods able to reduce the risk of breast cancer (BC).
Oestrogens have been recognised as one of the key factors
involved in the malignant transformation of breast cells in
both animal models and humans (Eisen, 1932; Bassler, 1970;
Miller & Bulbrook, 1980; Lippman et al., 1986; Henderson et
al., 1988). In contrast, the role of progestogens in the
aetiology of breast cancer is less established. Epidemiological
studies have provided conflicting results, ranging from a
protective effect to a deleterious effect of progestogen use on
BC risk. For instance, some studies on oral contraceptive
(OC) use found a reduced risk of breast cancer in
progestogen-only pill users as compared with never-users of
OCs (UK National Case-Control Study Group, 1989;
Ewertz, 1992). The risk of benign breast disease (BBD),
which is a known risk factor of BC (Dupont & Page, 1985;
Bodian, 1993), has been found to be lower in users of
combined OCs containing 19-nortestosterone when the
amount of this progestogen increased (Royal College of
General Practitioners, 1977; Brinton et al., 1981). The WHO
Collaborative Study (1991) on the use of medroxypro-
gesterone acetate (MPA) did not conclude that users and
non-users differ globally with respect to the risk of BC. In
contrast, the young women who had used OC, classified by
Pike et al. (1983) as having a high progestogen potency, had
a higher BC risk than the non-users of OCs. Studies on the
effects of combined hormonal replacement therapy (HRT) in
menopausal women provide another source of information
upon the effects of progestogens on BC risk. In a cohort
study of menopausal women receiving HRT, the BC risk was
found to be lower in women receiving a combined oest-
rogen-progestogen HRT than the BC risk of the general
population (Gambrell et al., 1983, 1986). However, this study
suffered several methodological weaknesses (Lee & Rubin,
1984; Ernster & Cummings, 1986}. More recently, in a cohort
of menopausal women, the BC risk was found to be higher,
but not significantly so, in women who had used combined
HRT for a long period of time (6-9 years) than in never-
users (Bergkvist et al., 1989). In the last report on this study
(Persson et al., 1992), the risk of BC was significantly in-
creased in the group of ever-users of combined HRT when
the elapsed time since first prescription was longer than 7
years. However, the exact duration of HRT use had not been
taken into account in this analysis. Recent meta-analyses on
HRT and risk of breast cancer, taking into account com-
bined oestrogen-progestogen use, did not conclude that
there is an excess risk in combined HRT users (Sillero-
Arenas et al., 1992; Colditz et al., 1993).
Controversial results have also been reported when con-
sidering the biological effects of progestogens on the normal
breast epithelial tissue. Several reviews addressing this issue
have been established in the past few years (Clarke & Suther-
land, 1990; Staffa et al., 1992; Stanford & Thomas, 1993). In
some studies (Bassler, 1970; Vogel et al., 1981), the mitotic
activity of breast epithelial cells was reported to be higher
during the follicular than during the luteal phase in normal
cycling women, while other authors have shown a peak of
mitotic activity of epithelial cells and DNA synthesis in the
late luteal phase (Masters et al., 1977; Meyer, 1977; Ferguson
& Anderson, 1981; Longacre & Bartow, 1986; Potten et al.,
1988). As this period of the menstrual cycle immediately
follows the peaks of secretion of both progesterone and
oestrogen, these authors inferred that progesterone is
involved in the promotion of breast epithelial cell mitoses, in
contrast to the well-documented antiproliferative effect of
progesterone on the endometrium (Clarke & Sutherland,
1990). However, this hypothesis remains to be confirmed as
the exact timing of the biopsy within the menstrual cycle was
sometimes questionable. Furthermore, the putative specific
role of progesterone, mainly based on a temporal relation-
ship, could not be separated from the possible effects of other
hormones, including oestrogen, also secreted at this period of
the cycle.
The term progestogens designates a large family of
molecules characterised by their high affinity for the pro-
gesterone receptors but with various binding capacities to
androgen receptors and different metabolisms (Mauvais-
Jarvis, 1983; Horwitz et al., 1985). This implies that they
should be considered as distinct, yet related, therapeutic
agents. More particularly, 19-nortestosterone derivatives have
been reported to have a strong antigonadotropic effect which
results in an inhibition of the ovarian oestrogen secretion
(Kuttenn et al., 1978; Barrat & Durand Chene, 1980); in
addition, they have an antioestrogenic effect on the endo-
metrial target cell level (Edgren & Sturtevant, 1976).
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Therefore, they have been widely used, at least in France, for
many years to treat vanous gynaecological disorders,
whenever a transitory suppression of the ovarian function
was necessary. Beneficial effects of the oral administration of
progestogens on hormone-dependent benign mammary symp-
toms have been reported (Mauvais-Jarvis, 1988), although
the benefits of local percutaneous administration remain
dubious (McFadyen et al., 1989). In the late 1970s, we
hypothesised that the chronic administration ofprogestogens,
and particularly 19-nortestosterone derivatives (Kuttenn et
al., 1978; Mauvais-Jarvis et al., 1982), at a dose which exerts
an antigonadotropic effect, could reduce the risk of breast
cancer. We present the results of a cohort study of 1,150
premenopausal women with BBD designed to investigate this
hypothesis.
Material and methods
Definition ofthepopulation
The study was conducted in two French hospitals, one in
Paris and one in the inner suburban area: the H6pital Necker
(NH) and the Institut Gustave Roussy (IGR) respectively.
Patients were considered eligible for the study if they were
French-born, 20-50 years old, premenopausal, had a diag-
nosis of BBD or isolated cyclical mastalgia, and if they had
no personal history ofbreast cancer or cancer at another site.
BBD included nodular hyperplasia, fibroadenoma, fibrocystic
disease, isolated cyst, isolated mastalgia and nipple discharge
(excluding galactorrhoea), diagnosed by a standard proce-
dure including, at least, general and breast clinical examina-
tion and mammography. The diagnosis was based on clinical
symptoms, bilateral breast palpation according to
Haagensen's (1971) description and radiological abnor-
malities. Additional ultrasonography, cytology and his-
tological verification was performed when necessary.
All consecutive eligible women seen for the first time in the
NH between 1976 and 1979, and in the IGR between 1977
and 1978, were included in the study. The cohort size was
based on a 10 year BC rate of 6% observed in a correspond-
ing group of premenopausal patients having presented with
BBD in the preceding years at the IGR (unpublished data)
and on the assumption of a 3-fold lower risk of BC among
progestogen users than among non-users (type I error, 0.05;
type II error, 0.05; unilateral situation). The calculation of
the sample size was performed using a standard method
(Freedman, 1982). The inclusion periods were determined in
order to recruit 600 patients in each centre. Patients diag-
nosed as having BC during the year following the first visit to
the clinic were excluded from the study, in order to exclude
pre-existing BC.
Data collection
Six specially trained gynaecologists were in charge of the
management of the study for both centres and filled in the
questionnaires. The initial and follow-up interviews were per-
formed by the senior consultant, who reported all relevant
information to the medical records. The data from the
medical records, including all the additional investigations,
were then transferred to the questionnaires.
The initial questionnaire included information about
known and suspected BC risk factors, the type of BBD and
procedure of diagnosis, including biopsy when performed,
and past therapies. The follow-up questionnaire included
detailed information on all hormonal treatments used
between the visits, i.e. the compliance to the hormonal
treatments previously prescribed and any additional treat-
ment, details on the main intercurrent events such as preg-
nancy and its outcome, the occurrence of menopause and
gynaecological or general disorders.
All patients who failed to return to the clinic were con-
tacted by mail. They were asked to complete and return a
similar questionnaire. This questionnaire requested inform-
ation about the evolution of the breast disease, the occur-
rence of new pathologies and their medical or surgical
treatments. The women were also asked for the name and
address of their physician, gynaecologist or surgeon, who was
subsequently contacted to verify the diagnosis of breast
disease, including breast cancer, or the disease-free status.
When a patient did not return the questionnaire, 2-3
further attempts to contact her by mail or phone were made.
When the patient had moved from her last known address,
the French telematic system (Minitel), which gives access to
the address of all registered clients of the French telecom-
munications public network (France Telecom), was used to
obtain her new address. Finally, when the patient could not
be found, her vital status was obtained from the Town hall
of her birthplace.
Classification ofprogestogens
The progestogens were categorized according to their type
and dosage into two categories. The first category comprised
19-nortestosterone derivatives administered for 15-20 days
per cycle and included lynestrenol, 10 mg daily (Orgametril),
norethisterone acetate, 10 mg daily (Primolut- Nor),
norethisterone, 10 mg daily (Norluten), and ethynodiol
diacetate, 8 mg daily (Lutometrodiol). The second one com-
prised all other progestogens such as pregnane or norpreg-
nane derivatives. No oestrogen was associated with these
progestogen treatments.
Statistical methods
The risk of BC was evaluated using two different methods:
(1) the Poisson regression analysis and (2) the Cox propor-
tional hazards model. In these two analyses, the follow-up
period started at the time of inclusion and ended in
December 1990. In the Poisson regression analysis, the
incidence rate ofbreast cancer was equal, for each considered
category, to the ratio of the observed breast cancers divided
by the number of the corresponding exposed women express-
ed in person-months. The person-months data correspond-
ing to the categories of the following time-varying
covariables, i.e. attained age and cumulated progestogen use,
were generated by means of a FORTRAN program adapted
from Pearce and Checkoway (1987). As the inclusion period
was restricted to only 4 years, the calendar time was not
added to the model. The Poisson regression, performed on
the person-month data by means of the statistical package
EGRET (1990), was used to estimate the attained age- and
cumulated progestogen use-adjusted incidence rates of breast
cancer.
The Cox proportional hazards model (Cox, 1972) was also
used, as it provides greater flexibility when adjusting simul-
taneously on several confounding variables. In this approach,
progestogen use during the follow-up period was considered
as a time-dependent variable; it was incorporated into the
model as a cumulated duration variable until the diagnosis of
BC or until a censoring event, i.e. the last visit to the clinic
or to the patient's personal physician, the death from another
origin than breast cancer, or a prophylactic bilateral mastec-
tomy. As the incidence of breast cancer is clearly age depen-
dent, the analysis was performed using attained age as a
time-varying covariable as well. In addition to a model using
only progestogen duration of use and age, the nine following
potential confounding variables were then added to the
model, i.e. type of BBD, fibrocystic disease vs all other types
of BBD, age at first visit (categories: <30; 30-34; 35-39;
40-45; >45 years old), history of breast cancer in mother or
sisters, age at menarche (< 12; 13; > 13 years old), parity (0;
1-2; 3+), age at first full-term pregnancy (less than 25 years
vs 25 years or more), oral contraceptive use (0; 1-4; >4
years), time elapsed since menopause during the follow-up
period and socioeconomic status coded according to the
French INSEE classification (INSEE, 1983) and clustered
into three categories (low, middle, high). The statistical
analysis was performed using the BMDP statistical softwarem G. PLU-BUREAU et al.
2L (Dixon, 1981). Interactions between progestogen use and
the above-mentioned confounding variables were also intro-
duced into the model and tested. Tests for statstical
significnce were based on the regression coefficients and
their standard errors.
Reits
Description ofthepopulation
A total of 1,150 patients were included: 618 at the IGR and
532 at NH. No patient refused the initial interview. Fifty-two
per cent of the patients had a fibrocystic disease, 27% a
fibroadenoma or nodular hyperplasia, 11% other physical
lesions and 10% isolated cyclical mastalgia. The diagnosis
was histologically confirmed in 28%, 22%, 25% and 0% of
the cases respectively. Progestogens had been prescribed to
766 patients (67%). The characteristics of ever-users accord-
ing to the main characteristics of the patients are shown in
Table I. The highest proportion ofever-users was observed in
women aged 35-39 with a high socioeconomic status, a
history of breast cancer in mother or sisters and an early age
at menarche. No significant difference in progestogen use was
Table I Progestogen use according to
found according to the other charactrstics of the popula-
tion, including the type of BBD. Menopause occurred in 527
women during the follow-up period. Of these, only 31%
received HRT (median duration of use 24 months). The
women who did not use progestogens had no other medical
treatment for their BBD. Oral contraceptives were mainly
used before BBD, and only 138 patients (12% of the women)
used OC after the disappearance of the BBD symptoms
(median duration of use 30 months).
Description ofthefollow-up
A total of 12,462 person-years was documented, and 82% of
the patients in the cohort had a follow-up exceeding 10 years.
The mean attrition rate for the patients lost to follow-up in
the cohort was 1.8% per year. Of the patients lost to follow-
up, six died from an unknown cause with an equal distribu-
tion among progestogen users and non-users (three patients
in each group). During the follow-up period, 44 patients were
diagnosed as having BC. All have been histologially verified.
In addition, two women died from a cancer at another site,
one from a non-malignant disease and two women under-
went a prophylactic bilateral mastectomy.
the characteristics of the patients in the
hort
Nwnber of Ever-users
Characteristics patients n % pa
Age at first visit (years)
20-29
35-39
40-50
Socioeconomic status
Low
Middle
High
Family history of breast cancer in
mother or sisters
No
Yes
Age at menarche (years)
8-12
13
14+
Number of chFldren
0
1-2
3+
Age at first full-term prgnancy (years)
18-24
25-29
30+
Oral contraceptive use (months)
0
1-48
49+
Type of BBD
Mastodynia
Adenofibroma
Fibrocystic disease
Other
Breast biopsy
No
Yes
Menopausal status"
Yes
225
373
552
164
501
485
147
272
347
92
323
351
65
73
63
56
64
72
1018 666 65
132 100 76
380
330
440
271
681
198
455
303
121
712
303
135
114
311
596
129
274
221
271
182
463
121
292
213
79
468
214
84
71
218
392
85
72
67
62
67
68
61
64
70
65
66
71
62
62
70
66
66
876 583 67
274 183 67
0.006
0.0003
0.02
0.006
0.19
0.21
0.16
0.41
0.94
Artificial 54 31 57
Natural 473 315 67
No 623 420 67 0.33
'P-vahe, test forhomogeneity between categories. bMenopause occurring during the
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Riskfactorsfor breast cancer
The characteristics of the population and the number of
observed BCs according to the main potential confounders
and the progestogen use are shown in Table II, together with
the corresponding-relative risks. The risk of the BC was
found to be significntly increased in women with a late age
at first visit and in women with a fibrocystic disease. None of
the other considered factors significantly modified the risk of
BC.
Progestogens and risk ofbreast cancer
The raw 10 year rates of breast cancer in untreated patients
and in patients who had received progestogen treatment were
5% (95% CI 2-7%) and 2% (95% CI 1-3%) respectively
(log-rank test, P = 0.03). A description of the number of
breast cancers by age and cumulated duration of progestogen
use is given in Table III. The risk of breast cancer associated
with cumulated progestogen use, estimated by the two statis-
tical methods, is shown in Table IV. The Poisson regression
analysis and the Cox model using age and progestogen dura-
tion of use gave consistent results. When all types of proges-
togens were pooled together, the relative risk of breast cancer
for users was not significantly different from unity, as com-
pared with non-users. When each type of progestogen was
considered separately, the three estimated risks of BC were
lower in 19-nortestosterone derivative users than in non-
users. In addition, a significant linear trend was observed
with the duration of 19-nortestosterone derivative use in the
adjusted model (P = 0.02). In all the statistical analyses, no
significant association was observed between ever-use or
duration of use of 'other progestogens' and the risk of BC.
None of the tested interactions was significant.
Bias assessment
To detect the potential bias due to the women lost to follow-
up, we have compared the percentages of patients lost to
follow-up during the first 10 years according to the main
characteristics of our population (Table V). The highest
percentage of patients lost to follow-up was observed in the
youngest patients, i.e. in patients who had the lowest risk of
BC. High percentages of loss to follow-up were also observed
in patients with fibroadenoma, nulliparous women and
patients without a history of breast biopsy, but these women
were also younger. When we estimated the potential number
of BCs occurring in the women lost to follow-up, based on
the 10 year rate according to the five age categories, only an
additional five BCs were expected. Therefore, it seems
unlikely that the number of BCs in women lost to follow up
could account for the difference observed between the treated
and untreated women and alter the results.
Since most of the patients recruited for the study had no
histologically verified BBD, additional analyses were per-
formed on subgroups of patients with different risks of BC,
such as patients with fibrocystic disease, patients with mastal-
gia and patients with histologically proven BBD. The risks of
BC in relation to progestogen use in each of these subgroups
of patients were similar to the risks of BC in the global
analysis.
Table H Relative risks of breast cancer (BC) associated with the main potential confounders
Progestogen Progestogen
non-users ever-users
Characteristics Total (BC) Total (BC) RR (95% Cib) pc
Age at first visit (years)
20-29 78 (2) 147 (1) 1.0d
35-39 101 (8) 272 (7) 2.8 (0.7-10.1)
40-50 205 (10) 347 (16) 7.4 (1.9-28.6) 0.0007e
Socioeconomic status
Low 72 (3) 92 (2) 1.0d
Midde 178 (11) 323 (14) 1.4 (0.5-3.7)
High 134 (6) 351 (8) 0.8 (0.3-2.4) 0.45e
Family history of breast cancer in
mother or sisters
No 352 (19) 666 (21) 1.0d
Yes 32 (1) 100 (3) 1.0 (0.3-3.0) 0.87
Age at menarche (years)
8-12 106 (3) 274 (10) 1.0d
13 109 (7) 221 (3) 0.8 (0.3-1.7)
14+ 169 (10) 271 (11) 1.3 (0.6-2.6) 0.43e
Number of children
0 89 (7) 182 (7) 1.0d
1-2 218 (10) 463 (15) 0.8 (0.4-1.6)
3.+ 77 (3) 121 (2) 0.6 (0.2-2.0) 0.33'
Age at first full-term pregnancy (years)
<25 163 (6) 292 (9) 1.0d
25+ 132 (7) 292 (8) 1.4 (0.6-2.8) 0.33
Type of BBD
Adenofibroma 93 (3) 218 (2) 1.0d
Mastodynia 43 (4) 71 (0) 2.5 (0.6-9.5) 0.22
Fibrocystic disease 204 (13) 392 (19) 2.8 (1.1-7.6) 0.04
Other 44 (0) 85 (3) 1.6 (0.4-6.6) 0.55
Breast biopsy
No 293 (17) 583 (16) 1.0"
Yes 91 (3) 183 (8) 1.0 (0.5-2.1) 0.94
Oral contraceptive use
No 244 (13) 468 (19) 1.0"
Yes 140 (7) 298 (5) 0.8 (0.4-1.6) 0.43
aRelative risk of breast cancer calculated from a multivariate Cox model taking into account all the factors and
stratified on progestogen use and menopausal status. "CI; confidence interval. 'P-value. Reference category. due,
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In a cohort study of 1,150 premenopausal women with BBD,
no modification of BC risk could be observed with overall
progestogen use. When the progestogens were separated into
19-nortestosterone derivatives and 'other progestogens', only
the 19-nortestosterone derivatives were significantly
associated with a decreased risk in breast cancer.
As BBD diagnosis was not histologically confirmed for all
women, data could not be analysed according to the
pathological criteria proposed by Dupont and Page in 1985
(non-proliferative disease, proliferative disease without atypia
or atypical hyperplasia). We do not think- that this lack of
information could have modified our conclusions, since the
results were not different in women with histologically proven
BBD, including fibrocystic disease (Dupont & Page, 1985),
and in women with mastalgia (Plu-Bureau et al., 1992),
although these subgroup analyses had a limited statistical
Tabl m Breast cancer counts in relation to the exposed person-months according to the different categories of
age and cumulated progestogen use along the follow-up period
Duration ofprogestogen use
Never-users 1-36 months 37-72 months >72 months
Age Person- Person- Person- Person-
(years) Cases months Cases months Cases months Cases months
Any type of progestogen
20-29 1 5,865 1 4,417 0 1,152 0 227
30-34 1 7,867 0 5,136 0 1,471 0 799
35-39 5 9,760 0 6,941 1 2,194 0 1,674
40-44 1 11,870 4 9,053 0 4,099 0 2,968
45+ 12 27,793 10 24,482 3 10,422 5 11,347
Total 20 63,155 15 50,029 4 19,338 5 17,015
19-Nortestosterone derivatives
20-29 1 6,271 1 4,273 0 1,001 0 133
30-34 1 9,089 0 4,626 0 1,008 0 529
35-39 5 11,940 1 6,437 0 1,390 0 840
40-44 3 15,163 2 8,065 0 3,161 0 1,636
45+ 19 36,638 6 21,686 3 8,453 2 7,198
Total 29 79,101 10 45,087 3 15,013 2 10,336
Other progestogens
20-29 2 9,850 0 1,752 0 84 0 0
30-34 1 12,187 0 2,664 0 366 0 61
35-39 5 15,099 1 4,343 0 810 0 336
40-44 2 19,527 3 6,587 0 1,435 0 445
45+ 18 49,603 9 19,112 2 3,788 1 1,488
Total 28 106,266 13 34,458 2 6,483 1 2,330
Table IV Relative risk of breast cancer (RR) associated with the cumulated duration of progestogen use
Number 95% 95% 95% Duration of of confidence confidence confidence
progestogen use Group breast interval interval interval (months) size cancers RR (p_trend)bpb Rc (p4 n)b jRd (P_trend)b
All categories ofprogestogens
0 384 20 1.OOe 1.OOe 1.00F
I-36 435 15 0.91 0.47-1.78 0.84 0.43-1.65 0.82 0.42-1.63 37-72 124 4 0.60 0.20-1.75 0.52 0.18-1.53 0.52 0.17-1.54 73+ 207 5 0.78 0.29-2.09 0.64 0.23-1.75 0.49 0.18-1.39
(0.41) (0.22) (0.11)
Ever use 766 24 0.81 0.45-1.47 0.72 0.40-1.32 0.68 0.37-1.25
19-Nortestosterone derivatives
0 551 29 1.00F l.00F L.00' 1-36 363 10 0.60 0.29-1.24 0.56 0.27-1.15 0.57 0.28-1.18 37-72 101 3 0.50 0.15-1.65 0.44 0.13-1.47 0.43 0.13-1.45 73+ 135 2 0.45 0.14-1.88 0.35 0.08-1.50 0.27 0.06-1.17
(0.08) (0.04) (0.02)
Ever use 599 15 0.55 0.30-1.04 0.49 0.26-0.93 0.48 0.25-0.90
Other progestogens
0 677 28 l.00F l.00 L.00' 1-36 377 13 1.33 0.68-2.57 1.25 0.64-2.43 1.20 0.61-2.38 37-72 69 2 1.04 0.25-4.39 0.84 0.20-3.59 0.71 0.17-3.05 73+ 27 1 1.41 0.19-10.4 1.15 0.16-8.52 0.93 0.12-7.04
(0.52) (0.79) (0.96)
Ever use 473 16 1.29 0.69-2.39 1.17 0.63-2.19 1.14 0.60-2.15
'Relative risk, calculated with a Poisson regression model, adjusted on age. bPvalnc; test for trend. rRelativersk calculated with a Cox model,adjusted on age. dRelativerisk caculated with a Cox model, adjusted on age, socioeconomic status, age at menarche, family history of breast cancer in first-degree relatives, type of benign breast disease, oral contraceptive use, parity, age at first full-term prgnancy and change in menopausal status during the follow-up period. 'Reference category.PROGESTOGEN USE AND BREAST CANCER 275
Table V Distribution of the patients lost to follow-up during the first 10 year period
after the inclusion in the study
Number of Lost to follow-up
Characteristics patients n % P
Age at first visit (years)
20-29 225 75 33
35-39 373 58 16
40-50 552 72 13 0.0001
Socioeconomic status
Low 164 25 15
Middle 501 81 16
High 485 99 20 0.14
Family history of breast cancer in
mother or sisters
No 1018 181 18
Yes 132 24 18 0.90
Age at menarche (years)
8-12 380 65 17
13 330 60 18
14+ 440 80 18 0.90
Number of children
0 271 72 27
1-2 681 105 15
3+ 198 28 14 0.0001
Age at first full-term pregnancy (years)
18-24 455 67 15
25-29 303 45 15
30+ 121 21 17 0.76
Type of BBD
Mastodynia 114 26 23
Adenofibroma 311 81 26
Fibrocystic disease 596 75 13
Other 129 23 18 0.001
Breast biopsy
No 876 174 20
Yes 274 31 11 0.001
aP-value, test for homogeneity between categories.
power. In addition, the observed 10 year incidence of BC in
the non-treated women (5%) was similar to those of another
cohort of histologically proven BBD (6%), from which the
theoretical size of our cohort was established.
Our study did not find any relationship between the main
risk factors for breast cancer, except for age at diagnosis and
the diagnosis of a fibrocystic disease. The limited number of
BCs observed during our follow-up period (44) could account
for this result. This number of BCs was even more reduced
(20) in the group of untreated women and drastically limited
the possibility of detecting a significant effect for these risk
factors, considering the observed beneficial effect of proges-
togen in the group of treated women, which could have
cancelled out the possibility of detecting a deleterious effect
of those risk factors for BC.
A possible source of bias in our results could have been
the fact that progestogens were more frequently prescribed to
patients with low risk of BC than to patients with high risk
of BC. However, this bias cannot be retained since the
percentage of women treated with progestogens was identical
among patients with fibrocystic disease (high risk of breast
cancer) and those with another BBD (66% vs 68%). In
addition, the percentage of progestogen users was
systematically higher in all the subgroups of patients with a
risk factor for BC, as shown in Table I. Conversely, the
observed effect might be explained by a deleterious effect of
the use of other sex hormones, such as oral contraceptives or
HRT in the group of women not exposed to progestogens.
However, no cancer occurred among the 164 menopausal
women who had used HRT, and only one cancer appeared
among the 138 patients who had used OC after the inclusion
in the study. In any case, if some unrecognised biases might
partially explain the magnitude of the decrease in the BC risk
after chronic use of 19-nortestosterone derivatives, it is
unlikely that they would reverse our conclusions and conceal
a deleterious effect of these hormones.
As the only significant result is associated with the dura-
tion of use, the reasons for discontinuing the treatment must
be considered. It is clear, from the clinical practice, that the
occurrence of side-effects, either metabolic or androgenic, is
an important cause of treatment discontinuation. We might
therefore wonder whether the patients who tolerated the
treatment were at lower risk of BC: if this assumption was
correct, one could speculate that the non-tolerance to 19-
nortestosterone derivatives would be a marker of BC suscep-
tibility in premenopausal women. Our data set did not allow
us to explore this hypothesis further.
Thus, our results suggest that the chronic administration of
19-nortestosterone derivatives might have a protective effect
on the risk of breast cancer in premenopausal women with
BBD. As the 19-nortestosterone derivatives are known to
differ from other progestogens by their affinity for the pro-
gesterone and androgen receptors, these results suggest that
different types of progestogens might have different effects on
the mammary gland (Staffa et al., 1992). This could partially
account for the controversy regarding the relationship
between progestogen use and the risk of breast cancer (Stan-
ford & Thomas, 1993). Indeed, only the long-term use of
pregnane derivatives such as MPA has been found to be
associated with a slight increase in breast cancer risk in some
specific subgroups of women (WHO Collaborative Study of
Neoplasia and Steroid Contraceptives, 1991). However, none
of the women in our cohort was exposed to this drug.
Epidemiological studies on the breast cancer risk
associated with the progestogen component of the oral con-
traceptives have shown contradictory results (UK National
Case-Control Study Group, 1989; Pike et al., 1983; Stadel et
al., 1985). The main difficulty remains to find a consensus276 G. PLU-BUREAU et al.
about a single scale of progestogen potency among the
different compounds (Dorflinger, 1985).
There is still no clear account of the role that progestogens
play in human breast cell proliferation, and the issue con-
tinues to be debated (Ferguson & Anderson, 1981; Kuttenn
et al., 1981; Key & Pike, 1988; Barrat et al., 1990). In a
recent study (Maudelonde et al., 1991), the use of the 19-
nortestosterone derivative, lynestrenol (10 mg daily, from day
5 to day 25 of the menstrual cycle) was shown to decrease
significantly the percentage of oestrogen receptor-stained
breast cells in women with BBD. This result suggests that
this drug may decrease the stimulatory effects of oestrogens
on the mammary gland by decreasing the number of func-
tional oestrogen receptors. Other biochemical studies indicate
that the antioestrogenic effects of 19-nortestosterone
derivatives on human non-cancerous breast tissues are
different from the effects observed with other classes of pro-
gestogens (Edgren & Sturtevant, 1976; Mauvais-Jarvis, 1986).
In contrast, in oestrogen receptor-positive breast cancer cell
lines (MCF7 and T47DC4), 19-nortestosterone derivatives
have been shown to stimulate cell growth in vitro (Jeng et al.,
1992). However, a great amount of caution must prevail
when extrapolating the findings of in vitro studies on breast
cancer cell lines to the situation of non-cancerous breast cells
in vivo; there is still no definitive evidence to support the
likelihood of similar reactions both in vitro and in vivo, or an
identity ofaction ofprogestogens on both non-cancerous and
cancerous epithelial breast cells (Longman & Buehring,
1987).
To our knowledge, this study is the first specifically
designed to analyse the effect of oral isolated progestogen use
on breast cancer risk in women with BBD. The conclusions
of the present epidemiological cohort study suggest that some
categories of progestogens, administered at a dose known to
exert an antigonadotropic effect, might be useful in breast
cancer prevention. This is important at a time when large
randomised multicentric trials on breast cancer prevention
(Powles et al., 1989; Fisher et al., 1992) are investigating the
efficiency of the antioestrogenic agent tamoxifen.
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